Pharmaceutical Litigation News

When your child is diagnosed with a birth defect, there is an immediate list-making response. Duties, tasks and intentions pile up in your mind of doctors to consult, appointments to make, tests to run, answers to find. One task that may not immediately occur to you, however, is one of the most important: the task … Read more

Every year, about a quarter of a million babies are born in the state of New York. Between 3 and 4 percent of these children suffer from some type of physical or mental defect. Some come as a result of genetic factors, some are due to exposure to harmful chemicals or pharmaceutical drugs and others result … Read more

Earlier this month, pharmaceutical giant Merck & Co. offered to settle thousands of pending lawsuits surrounding its contraceptive device NuvaRing. Since 2008, more than 3,800 cases have been brought against the company from NuvaRing users subjected to stroke-causing blood clots without sufficient warning. The price for resolving these complaints? $100 million. ‘For Me, It’s Easy’ NuvaRing … Read more

The morning sickness drug Diclegis may have only been approved by the Food and Drug Administration recently, but Betty Mekdeci has known it well for nearly 40 years. Diclegis is a combination of pyridoxine (vitamin B6) and doxylamine being offered by Canada’s Duchesnay Inc. This drug combination was once sold under the name Bendectin before … Read more

Finasteride used in Proscar & Propecia (Merck and Co Inc.) and dutasteride used in closely related Avodart & Jalyn (GlaxoSmithKline) are prescribed to treat baldness & a common urological condition called benign prostatic hyperplasia (BPH). The drugs belong to a class called 5-alpha reductase inhibitors (5-ARI), which work by blocking androgen. This helps reduce the enlarged … Read more

In 1992, the Food and Drug Administration (FDA) implemented the Prescription Drug User Fee Act (PDUFA). According to the Act, funding for the FDA’s drug approval process would come directly from the pharmaceutical industry. More specifically, the act mandated that drug manufacturers pay a substantial fee for each New Drug Application (NDA) they wanted reviewed. … Read more